恒瑞医药取得药物临床试验批准通知

Core Viewpoint - Heng Rui Medicine (600276.SH) and its subsidiaries have received approval from the National Medical Products Administration for clinical trials of multiple drugs, indicating a significant advancement in their oncology pipeline [1] Group 1: Clinical Trial Approvals - The company and its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd., have been granted clinical trial approval notices for HRS-4508 tablets, SHR-A1811 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [1] - The clinical trials will include an open-label, multicenter Phase I/II study of HRS-4508 in combination with other anti-tumor therapies for solid tumors with abnormal HER2 pathways [1]